47 results on '"Furuyama W"'
Search Results
2. Impact of Health Literacy on Satisfaction Following Inflatable Penile Prosthesis Surgery
- Author
-
Bhalla, R, Furuyama, W, Calvert, J, Ball, M, Dropkin, B, Milam, D, Kaufman, M, and Johnsen, N
- Published
- 2022
- Full Text
- View/download PDF
3. Marburg virus exploits the Rab11-mediated endocytic pathway in viral-particle production.
- Author
-
Furuyama W, Yamada K, Sakaguchi M, Marzi A, and Nanbo A
- Subjects
- Humans, Animals, Microtubules metabolism, Microtubules virology, Virus Release, Cell Line, HEK293 Cells, Virus Replication, rab GTP-Binding Proteins metabolism, rab GTP-Binding Proteins genetics, Marburgvirus physiology, Marburgvirus genetics, Marburgvirus metabolism, Viral Matrix Proteins metabolism, Viral Matrix Proteins genetics, Endocytosis, Virion metabolism
- Abstract
Filoviruses produce viral particles with characteristic filamentous morphology. The major viral matrix protein, VP40, is trafficked to the plasma membrane and promotes viral particle formation and subsequent viral egress. In the present study, we assessed the role of the small GTPase Rab11-mediated endocytic pathway in Marburg virus (MARV) particle formation and budding. Although Rab11 was predominantly localized in the perinuclear region, it exhibited a more diffuse distribution in the cytoplasm of cells transiently expressing MARV VP40. Rab11 was incorporated into MARV-like particles. Expression of the dominant-negative form of Rab11 and knockdown of Rab11 decreased the amount of VP40 fractions in the cell periphery. Moreover, downregulation of Rab11 moderately reduced the release of MARV-like particles and authentic MARV. We further demonstrated that VP40 induces the distribution of the microtubule network toward the cell periphery, which was partly associated with Rab11. Depolymerization of microtubules reduced the accumulation of VP40 in the cell periphery along with viral particle formation. VP40 physically interacted with α-tubulin, a major component of microtubules, but not with Rab11. Taken together, these results suggested that VP40 partly interacts with microtubules and facilitates their distribution toward the cell periphery, leading to the trafficking of transiently tethering Rab11-positive vesicles toward the cell surface. As we previously demonstrated the role of Rab11 in the formation of Ebola virus particles, the results here suggest that filoviruses in general exploit the vesicle-trafficking machinery for proper virus-particle formation and subsequent egress. These pathways may be a potential target for the development of pan-filovirus therapeutics.IMPORTANCEFiloviruses, including Marburg and Ebola viruses, produce distinct filamentous viral particles. Although it is well known that the major viral matrix protein of these viruses, VP40, is trafficked to the cell surface and promotes viral particle production, details regarding the associated molecular mechanisms remain unclear. To address this knowledge gap, we investigated the role of the small GTPase Rab11-mediated endocytic pathway in this process. Our findings revealed that Marburg virus exploits the Rab11-mediated vesicle-trafficking pathway for the release of virus-like particles and authentic virions in a microtubule network-dependent manner. Previous findings demonstrated that Rab11 is also involved in Ebola virus-particle production. Taken together, these data suggest that filoviruses, in general, may hijack the microtubule-dependent vesicle-trafficking machinery for productive replication. Therefore, this pathway presents as a potential target for the development of pan-filovirus therapeutics., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
4. Household Toilet and Sanitation Insecurity is Associated With Urinary Symptoms, Psychosocial Burden, and Compensatory Bladder Behaviors.
- Author
-
Sebesta E, Furuyama W, Dmochowski R, and Stuart Reynolds W
- Subjects
- Humans, Male, Female, Middle Aged, Adult, United States epidemiology, Aged, Urination Disorders psychology, Urination Disorders epidemiology, Urination Disorders etiology, Surveys and Questionnaires, Family Characteristics, Bathroom Equipment, Cost of Illness, Sanitation, Toilet Facilities
- Abstract
Objective: To investigate whether being "at-risk" for toilet and sanitation insecurity in the United States is associated with urinary symptoms, voiding behaviors, and psychosocial burden. Based on census data, nearly 2 million people in the United States do not have access to adequate plumbing. More may have inconsistent access related to cost, inadequate facilities for the number of people in a home, or declining regional infrastructure. The effects of inadequate access in the United States are poorly characterized., Methods: This is a secondary analysis of a community-based sample of adults electronically recruited to complete questionnaires on clinical and sociodemographic information, living situations, home toilets and plumbing, urinary symptoms, compensatory bladder behaviors, and psychosocial burden. Multivariable logistic regression was used to assess for associations between being at-risk for toilet and sanitation insecurity and urinary and psychosocial symptoms. Linear regression was used to assess for association with adopting compensatory bladder behaviors., Results: This sample included 4218 participants, of whom 17% were identified as being at-risk for toilet and sanitation insecurity. Being at-risk for toilet and sanitation insecurity was associated with worse overall urinary symptoms and greater bother from these symptoms, in addition to worse self-assessed mental and physical health, anxiety, stress, depression, and fewer social supports. Finally, those at-risk for toilet and sanitation insecurity were more likely to adopt burdensome and unhealthy compensatory bladder behaviors., Conclusion: As with other social determinants of health, toilet and sanitation insecurity may be an under-appreciated contributor to urinary symptoms, unhealthy toileting behaviors, and psychosocial distress., Competing Interests: Declaration of Competing Interest Dr. W Stuart Reynolds—source of funding: Grants UL1 TR000445 from NCATS/NIH and R01DK128293 and R01DK129624 from NIDDK; the remaining authors declare that they have no conflict of interest. Institutional Review Board-approved: Study #211445., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus.
- Author
-
Ng TW, Furuyama W, Wirchnianski AS, Saavedra-Ávila NA, Johndrow CT, Chandran K, Jacobs WR Jr, Marzi A, and Porcelli SA
- Subjects
- Animals, Mice, T-Lymphocytes, Helper-Inducer immunology, Vaccination methods, Mice, Inbred C57BL, Female, Humans, Disease Models, Animal, Receptors, IgG immunology, Vaccine Development, Immunoglobulin Class Switching, Immunization, BCG Vaccine immunology, Ebolavirus immunology, Hemorrhagic Fever, Ebola prevention & control, Hemorrhagic Fever, Ebola immunology, Ebola Vaccines immunology, Ebola Vaccines administration & dosage, Antibodies, Viral immunology, Antibodies, Viral blood
- Abstract
Previous studies have demonstrated the efficacy and feasibility of an anti-viral vaccine strategy that takes advantage of pre-existing CD4
+ helper T (Th) cells induced by Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccination. This strategy uses immunization with recombinant fusion proteins comprised of a cell surface expressed viral antigen, such as a viral envelope glycoprotein, engineered to contain well-defined BCG Th cell epitopes, thus rapidly recruiting Th cells induced by prior BCG vaccination to provide intrastructural help to virus-specific B cells. In the current study, we show that Th cells induced by BCG were localized predominantly outside of germinal centers and promoted antibody class switching to isotypes characterized by strong Fc receptor interactions and effector functions. Furthermore, BCG vaccination also upregulated FcγR expression to potentially maximize antibody-dependent effector activities. Using a mouse model of Ebola virus (EBOV) infection, this vaccine strategy provided sustained antibody levels with strong IgG2c bias and protection against lethal challenge. This general approach can be easily adapted to other viruses, and may be a rapid and effective method of immunization against emerging pandemics in populations that routinely receive BCG vaccination., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Ng, Furuyama, Wirchnianski, Saavedra-Ávila, Johndrow, Chandran, Jacobs, Marzi and Porcelli.)- Published
- 2024
- Full Text
- View/download PDF
6. Mapping of susceptibility loci for Ebola virus pathogenesis in mice.
- Author
-
Schäfer A, Marzi A, Furuyama W, Catanzaro NJ, Nguyen C, Haddock E, Feldmann F, Meade-White K, Thomas T, Hubbard ML, Gully KL, Leist SR, Hock P, Bell TA, De la Cruz GE, Midkiff BR, Martinez DR, Shaw GD, Miller DR, Vernon MJ, Graham RL, Cowley DO, Montgomery SA, Schughart K, de Villena FPM, Wilkerson GK, Ferris MT, Feldmann H, and Baric RS
- Subjects
- Animals, Mice, Mice, Knockout, Chromosome Mapping, Liver pathology, Liver metabolism, Humans, Mice, Inbred C57BL, Female, Male, Hemorrhagic Fever, Ebola virology, Hemorrhagic Fever, Ebola genetics, Hemorrhagic Fever, Ebola pathology, Quantitative Trait Loci genetics, Ebolavirus pathogenicity, Ebolavirus genetics, Genetic Predisposition to Disease
- Abstract
Ebola virus (EBOV), a major global health concern, causes severe, often fatal EBOV disease (EVD) in humans. Host genetic variation plays a critical role, yet the identity of host susceptibility loci in mammals remains unknown. Using genetic reference populations, we generate an F2 mapping cohort to identify host susceptibility loci that regulate EVD. While disease-resistant mice display minimal pathogenesis, susceptible mice display severe liver pathology consistent with EVD-like disease and transcriptional signatures associated with inflammatory and liver metabolic processes. A significant quantitative trait locus (QTL) for virus RNA load in blood is identified in chromosome (chr)8, and a severe clinical disease and mortality QTL is mapped to chr7, which includes the Trim5 locus. Using knockout mice, we validate the Trim5 locus as one potential driver of liver failure and mortality after infection. The identification of susceptibility loci provides insight into molecular genetic mechanisms regulating EVD progression and severity, potentially informing therapeutics and vaccination strategies., Competing Interests: Declaration of interests D.O.C. is employed by, has equity ownership in, and serves on the board of directors of TransViragen, the company that has been contracted by UNC-Chapel Hill to manage its Animal Models Core Facility. R.S.B. is a member of advisory boards for VaxArt, Takeda, and Invivyd, focused on unrelated projects., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Phylogenetic analysis of the promoter element 2 of paramyxo- and filoviruses.
- Author
-
Ashida S, Kojima S, Okura T, Kato F, Furuyama W, Urata S, and Matsumoto Y
- Subjects
- Paramyxoviridae genetics, Paramyxoviridae classification, Humans, RNA, Viral genetics, Evolution, Molecular, Animals, Promoter Regions, Genetic genetics, Phylogeny, Genome, Viral genetics, Filoviridae genetics, Filoviridae classification
- Abstract
Paramyxo- and filovirus genomes are equipped with bipartite promoters at their 3 ' ends to initiate RNA synthesis. The two elements, the primary promoter element 1 (PE1) and the secondary promoter element 2 (PE2), are separated by a spacer region that must be precisely a multiple of 6 nucleotides (nts), indicating these viruses adhere to the "rule of six." However, our knowledge of PE2 has been limited to a narrow spectrum of virus species. In this study, a comparative analysis of 1,647 paramyxoviral genomes from a public database revealed that the paramyxovirus PE2 can be clearly categorized into two distinct subcategories: one marked by C repeats at every six bases (exclusive to the subfamily Orthoparamyxovirinae ) and another characterized by CG repeats every 6 nts (observed in the subfamilies Avulavirinae and Rubulavirinae ). This unique pattern collectively mirrors the evolutionary lineage of these subfamilies. Furthermore, we showed that PE2 of the Rubulavirinae , with the exception of mumps virus, serves as part of the gene-coding region. This may be due to the fact that the Rubulavirinae are the only paramyxoviruses that cannot propagate without RNA editing. Filoviruses have three to eight consecutive uracil repeats every six bases (UN
5 ) in PE2, which is located in the 3 ' end region of the genome. We obtained PE2 sequences from 2,195 filoviruses in a public database and analyzed the sequence conservation among virus species. Our results indicate that the continuity of UN5 hexamers is consistently maintained with a high degree of conservation across virus species., Importance: The genomic intricacies of paramyxo- and filoviruses are highlighted by the bipartite promoters-promoter element 1 (PE1) and promoter element 2 (PE2)-at their 3 ' termini. The spacer region between these elements follows the "rule of six," crucial for genome replication. By a comprehensive analysis of paramyxoviral genome sequences, we identified distinct subcategories of PE2 based on C and CG repeats that were specific to Orthoparamyxovirinae and Avulavirinae / Rubulavirinae , respectively, mirroring their evolutionary lineages. Notably, the PE2 of Rubulavirinae is integrated into the gene-coding region, a unique trait potentially linked to its strict dependence on RNA editing for virus growth. This study also focused on the PE2 sequences in filovirus genomes. The strict conservation of the continuity of UN5 among virus species emphasizes its crucial role in viral genome replication., Competing Interests: The authors declare no conflict of interest.- Published
- 2024
- Full Text
- View/download PDF
8. Micro-second time-resolved X-ray single-molecule internal motions of SARS-CoV-2 spike variants.
- Author
-
Sasaki D, Arai T, Yang Y, Kuramochi M, Furuyama W, Nanbo A, Sekiguchi H, Morone N, Mio K, and Sasaki YC
- Abstract
Single-molecule intramolecular dynamics were successfully measured for three variants of SARS-CoV-2 spike protein, alpha: B.1.1.7, delta: B.1.617, and omicron: B.1.1.529, with a time resolution of 100 μs using X-rays. The results were then compared with respect to the magnitude and directions of motions for the three variants. The largest 3-D intramolecular movement was observed for the omicron variant irrespective of ACE2 receptor binding. A more detailed analysis of the intramolecular motions revealed that the distribution state of intramolecular motion for the three variants was completely different with and without ACE2 receptor binding. The molecular dynamics for the trimeric spike protein of the omicron variant increased when ACE2 binding occurred. At that time, the diffusion constant increased from 71.0 [mrad
2 /ms] to 91.1 [mrad2 /ms]., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yuji C. Sasaki reports financial support was provided by Japan Science and Technology Agency. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)- Published
- 2024
- Full Text
- View/download PDF
9. A Single Case Observation: Is the Ebola Virus Soluble Glycoprotein an Indicator of Viral Recrudescence?
- Author
-
Furuyama W, Davey RT, Chertow DS, and Marzi A
- Subjects
- Humans, Glycoproteins, Africa, Western, Maryland, Ebolavirus genetics, Hemorrhagic Fever, Ebola
- Abstract
This case study investigated the long-term expression dynamics of Ebola virus (EBOV) soluble glycoprotein (sGP) in the serum of a patient who was infected with EBOV in West Africa and recovered from acute Ebola virus disease (EVD) at the National Institutes of Health Clinical Center in Bethesda, Maryland. Samples from this patient were collected during acute EVD and during convalescence up to day 361 following illness onset. Although blood samples were negative by reverse transcription-quantitative polymerase chain reaction after recovery from acute EVD, we detected small amounts of EBOV sGP in the serum of the patient long after recovery, potentially indicating viral recrudescence. As this was only observed in a single patient, additional longitudinal patient samples are needed to confirm our hypothesis that EBOV sGP may be an indicator of viral recrudescence long after recovery from acute EVD., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
- Published
- 2023
- Full Text
- View/download PDF
10. Atypical Ebola Virus Disease in a Rhesus Macaque.
- Author
-
Marzi A, Hanley PW, Furuyama W, Haddock E, Martens CA, Scott DP, and Feldmann H
- Subjects
- Animals, Humans, Macaca mulatta, Acute Disease, Disease Progression, Hemorrhagic Fever, Ebola, Ebolavirus
- Abstract
Ebola virus (EBOV)-Makona infected more than 30 000 people from 2013 to 2016 in West Africa, among them many health care workers including foreign nationals. Most of the infected foreign nationals were evacuated and treated in their respective home countries, resulting in detailed reports of the acute disease following EBOV infection as well as descriptions of symptoms now known as post-Ebola syndrome, which occurred months after the infection. Symptoms associated with this syndrome include uveitis and neurological manifestations. In 1 of our EBOV-Makona nonhuman primate (NHP) studies, 1 NHP was euthanized on day 28 after infection having completely recovered from the acute disease. During convalescence, this NHP developed neurological signs and acute respiratory distress requiring euthanasia. The organ tropism had changed with high virus titers in lungs, brain, eye, and reproductive organs but no virus in the typical target organs for acute EBOV infection. This in part reflects sequelae described for EBOV survivors albeit developing quicker after recovery from acute disease., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
- Published
- 2023
- Full Text
- View/download PDF
11. Development of an imaging system for visualization of Ebola virus glycoprotein throughout the viral lifecycle.
- Author
-
Furuyama W, Sakaguchi M, Yamada K, and Nanbo A
- Abstract
Ebola virus (EBOV) causes severe EBOV disease (EVD) in humans and non-human primates. Currently, limited countermeasures are available, and the virus must be studied in biosafety level-4 (BSL-4) laboratories. EBOV glycoprotein (GP) is a single transmembrane protein responsible for entry into host cells and is the target of multiple approved drugs. However, the molecular mechanisms underlying the intracellular dynamics of GP during EBOV lifecycle are poorly understood. In this study, we developed a novel GP monitoring system using transcription- and replication-competent virus-like particles (trVLPs) that enables the modeling of the EBOV lifecycle under BSL-2 conditions. We constructed plasmids to generate trVLPs containing the coding sequence of EBOV GP, in which the mucin-like domain (MLD) was replaced with fluorescent proteins. The generated trVLP efficiently replicated over multiple generations was similar to the wild type trVLP. Furthermore, we confirmed that the novel trVLP system enabled real-time visualization of GP throughout the trVLP replication cycle and exhibited intracellular localization similar to that of wild type GP. In summary, this novel monitoring system for GP will enable the characterization of the molecular mechanism of the EBOV lifecycle and can be applied for the development of therapeutics against EVD., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Furuyama, Sakaguchi, Yamada and Nanbo.)
- Published
- 2022
- Full Text
- View/download PDF
12. A platform technology for generating subunit vaccines against diverse viral pathogens.
- Author
-
Young A, Isaacs A, Scott CAP, Modhiran N, McMillan CLD, Cheung STM, Barr J, Marsh G, Thakur N, Bailey D, Li KSM, Luk HKH, Kok KH, Lau SKP, Woo PCY, Furuyama W, Marzi A, Young PR, Chappell KJ, and Watterson D
- Subjects
- Animals, Antibodies, Neutralizing, Antibodies, Viral, Humans, Pandemics, Spike Glycoprotein, Coronavirus, Technology, Vaccines, Subunit, COVID-19, Middle East Respiratory Syndrome Coronavirus, Viral Vaccines
- Abstract
The COVID-19 pandemic response has shown how vaccine platform technologies can be used to rapidly and effectively counteract a novel emerging infectious disease. The speed of development for mRNA and vector-based vaccines outpaced those of subunit vaccines, however, subunit vaccines can offer advantages in terms of safety and stability. Here we describe a subunit vaccine platform technology, the molecular clamp, in application to four viruses from divergent taxonomic families: Middle Eastern respiratory syndrome coronavirus (MERS-CoV), Ebola virus (EBOV), Lassa virus (LASV) and Nipah virus (NiV). The clamp streamlines subunit antigen production by both stabilising the immunologically important prefusion epitopes of trimeric viral fusion proteins while enabling purification without target-specific reagents by acting as an affinity tag. Conformations for each viral antigen were confirmed by monoclonal antibody binding, size exclusion chromatography and electron microscopy. Notably, all four antigens tested remained stable over four weeks of incubation at 40°C. Of the four vaccines tested, a neutralising immune response was stimulated by clamp stabilised MERS-CoV spike, EBOV glycoprotein and NiV fusion protein. Only the clamp stabilised LASV glycoprotein precursor failed to elicit virus neutralising antibodies. MERS-CoV and EBOV vaccine candidates were both tested in animal models and found to provide protection against viral challenge., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Young, Isaacs, Scott, Modhiran, McMillan, Cheung, Barr, Marsh, Thakur, Bailey, Li, Luk, Kok, Lau, Woo, Furuyama, Marzi, Young, Chappell and Watterson.)
- Published
- 2022
- Full Text
- View/download PDF
13. Impact of Health Literacy on Satisfaction Following Male Prosthetic Surgery.
- Author
-
Bhalla RG, Furuyama W, Calvert JK, Ball M, Dropkin BM, Milam DF, Kaufman MR, and Johnsen NV
- Subjects
- Humans, Male, Patient Satisfaction, Personal Satisfaction, Quality of Life, Retrospective Studies, Erectile Dysfunction surgery, Health Literacy, Penile Implantation methods, Penile Prosthesis
- Abstract
Objective: To determine whether a patient's health literacy impacts patient satisfaction following inflatable penile prosthesis (IPP) or artificial urinary sphincter (AUS) placement., Materials and Methods: A retrospective study of patients who underwent IPP or AUS between January 1, 2016 and July 31, 2020 was performed. A telephone questionnaire assessed overall satisfaction and if patients would undergo surgery again. Health literacy was measured using the Brief Health Literacy Screen (BHLS). Multivariate ordinal logistic regression was used to assess the association between health literacy and patient satisfaction., Results: At a median follow up of 2.4 years, 113 (70%) of the 162 IPP patients were either satisfied or very satisfied with their procedure and 120 (74%) patients would undergo surgery again. Of the 76 AUS patients, 65 (86%) were either satisfied or very satisfied with their procedure and 65 (86%) patients would undergo surgery again. After adjustment for potential confounders, increasing BHLS score was significantly associated with satisfaction for both IPP (OR 1.31, 95% CI 1.11-1.54; P = .001) and AUS surgery (OR 1.25, 95% CI 1.02-1.56; P = .034), as well as with likelihood of undergoing IPP surgery again (OR 1.53, 95% CI 1.25-1.87; P <.001). BHLS was not associated, however, with likelihood of undergoing AUS surgery again (P = .403)., Conclusion: Men with lower health literacy are less likely to be satisfied following prosthetic surgery. The BHLS is an important tool that can be used to identify patients who may benefit from increased preoperative counseling to improve patient expectations and quality of life following prosthetic surgery., Competing Interests: Declaration of conflicts of interest National Principal Investigator for Boston Scientific (MRK); Consultant Boston Scientific (DFM), (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
14. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
- Author
-
Okuya K, Hattori T, Saito T, Takadate Y, Sasaki M, Furuyama W, Marzi A, Ohiro Y, Konno S, Hattori T, and Takada A
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, Complement C1q, Humans, Immunoglobulin G, Receptors, IgG, SARS-CoV-2, Antibody-Dependent Enhancement, COVID-19
- Abstract
Antibody-dependent enhancement (ADE) of infection is generally known for many viruses. A potential risk of ADE in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has also been discussed since the beginning of the coronavirus disease 2019 (COVID-19) pandemic; however, clinical evidence of the presence of antibodies with ADE potential is limited. Here, we show that ADE antibodies are produced by SARS-CoV-2 infection and the ADE process can be mediated by at least two different host factors, Fcγ receptor (FcγR) and complement component C1q. Of 89 serum samples collected from acute or convalescent COVID-19 patients, 62.9% were found to be positive for SARS-CoV-2-specific IgG. FcγR- and/or C1q-mediated ADE were detected in 50% of the IgG-positive sera, whereas most of them showed neutralizing activity in the absence of FcγR and C1q. Importantly, ADE antibodies were found in 41.4% of the acute COVID-19 patients. Neutralizing activity was also detected in most of the IgG-positive sera, but it was counteracted by ADE in subneutralizing conditions in the presence of FcγR or C1q. Although the clinical importance of ADE needs to be further investigated with larger numbers of COVID-19 patient samples, our data suggest that SARS-CoV-2 utilizes multiple mechanisms of ADE. C1q-mediated ADE may particularly have a clinical impact since C1q is present at high concentrations in plasma and its receptors are ubiquitously expressed on the surfaces of many types of cells, including respiratory epithelial cells, which SARS-CoV-2 primarily infects. IMPORTANCE Potential risks of antibody-dependent enhancement (ADE) in the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been discussed and the proposed mechanism mostly depends on the Fc gamma receptor (FcγR). However, since FcγRs are exclusively expressed on immune cells, which are not primary targets of SARS-CoV-2, the clinical importance of ADE of SARS-CoV-2 infection remains controversial. Our study demonstrates that SARS-CoV-2 infection induces antibodies that increase SARS-CoV-2 infection through another ADE mechanism in which complement component C1q mediates the enhancement. Although neutralizing activity was also detected in the serum samples, it was counteracted by ADE in the presence of FcγR or C1q. Considering the ubiquity of C1q and its cellular receptors, C1q-mediated ADE may more likely occur in respiratory epithelial cells, which SARS-CoV-2 primarily infects. Our data highlight the importance of careful monitoring of the antibody properties in COVID-19 convalescent and vaccinated individuals.
- Published
- 2022
- Full Text
- View/download PDF
15. VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern.
- Author
-
O'Donnell KL, Gourdine T, Fletcher P, Shifflett K, Furuyama W, Clancy CS, and Marzi A
- Abstract
The continued progression of the COVID-19 pandemic can partly be attributed to the ability of SARS-CoV-2 to mutate and introduce new viral variants. Some of these variants with the potential to spread quickly and conquer the globe are termed variants of concern (VOC). The existing vaccines implemented on a global scale are based on the ancestral strain, which has resulted in increased numbers of breakthrough infections as these VOC have emerged. It is imperative to show protection against VOC infection with newly developed vaccines. Previously, we evaluated two vesicular stomatitis virus (VSV)-based vaccines expressing the SARS-CoV-2 spike protein alone (VSV-SARS2) or in combination with the Ebola virus glycoprotein (VSV-SARS2-EBOV) and demonstrated their fast-acting potential. Here, we prolonged the time to challenge; we vaccinated hamsters intranasally (IN) or intramuscularly 28 days prior to infection with three SARS-CoV-2 VOC-the Alpha, Beta, and Delta variants. IN vaccination with either the VSV-SARS2 or VSV-SARS2-EBOV resulted in the highest protective efficacy as demonstrated by decreased virus shedding and lung viral load of vaccinated hamsters. Histopathologic analysis of the lungs revealed the least amount of lung damage in the IN-vaccinated animals regardless of the challenge virus. This data demonstrates the ability of a VSV-based vaccine to not only protect from disease caused by SARS-CoV-2 VOC but also reduce viral shedding., Competing Interests: The authors declare no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
16. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
- Author
-
Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, and Marzi A
- Subjects
- Animals, Antibodies, Viral genetics, Antibodies, Viral immunology, Hemorrhagic Fever, Ebola genetics, Hemorrhagic Fever, Ebola immunology, Hemorrhagic Fever, Ebola prevention & control, SARS-CoV-2, Vaccination methods, Vesiculovirus genetics, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines therapeutic use, Ebola Vaccines genetics, Ebola Vaccines immunology, Ebola Vaccines therapeutic use, Ebolavirus genetics, Ebolavirus immunology, Macaca mulatta immunology, Vesicular Stomatitis genetics, Vesicular Stomatitis immunology, Vesicular Stomatitis prevention & control
- Abstract
The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single-dose, fast-acting vesicular stomatitis virus (VSV)-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (i.m.) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (i.n.) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to results for control animals. While both i.m. and i.n. vaccination induced neutralizing antibody titers, only i.m. vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of i.m. vaccinated animals only. Overall, the data demonstrate that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study. IMPORTANCE The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines Agency and the U.S. Food and Drug Administration for human use against the deadly disease. Here, we demonstrate the protective efficacy of a VSV-EBOV-based COVID-19 vaccine against challenge in nonhuman primates (NHPs). When a single dose of the VSV-SARS2-EBOV vaccine was administered intramuscularly (i.m.), the NHPs were protected from COVID-19 within 10 days. In contrast, if the vaccine was administered intranasally, there was no benefit from the vaccine and the NHPs developed pneumonia. The i.m. vaccinated NHPs quickly developed antigen-specific IgG, including neutralizing antibodies. Transcriptional analysis highlighted the development of protective innate and adaptive immune responses in the i.m. vaccination group only.
- Published
- 2022
- Full Text
- View/download PDF
17. Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters.
- Author
-
O'Donnell KL, Clancy CS, Griffin AJ, Shifflett K, Gourdine T, Thomas T, Long CM, Furuyama W, and Marzi A
- Subjects
- Animals, Antibodies, Viral blood, Antibodies, Viral immunology, COVID-19 blood, COVID-19 immunology, COVID-19 virology, COVID-19 Vaccines immunology, Chlorocebus aethiops, Cricetinae, Disease Models, Animal, Ebolavirus genetics, Female, Humans, Immunogenicity, Vaccine, Immunoglobulin G blood, Immunoglobulin G immunology, Male, Plasmids, Spike Glycoprotein, Coronavirus genetics, T-Lymphocytes immunology, Treatment Outcome, Vero Cells, Vesicular stomatitis Indiana virus genetics, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Ebolavirus immunology, Pandemics prevention & control, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology, Vaccination methods, Vesicular stomatitis Indiana virus immunology
- Abstract
The ongoing COVID-19 pandemic has resulted in global effects on human health, economic stability, and social norms. The emergence of viral variants raises concerns about the efficacy of existing vaccines and highlights the continued need for the development of efficient, fast-acting, and cost-effective vaccines. Here, we demonstrate the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based vaccines encoding the SARS-CoV-2 spike protein either alone (VSV-SARS2) or in combination with the Ebola virus glycoprotein (VSV-SARS2-EBOV). Intranasally vaccinated hamsters showed an early CD8
+ T cell response in the lungs and a greater antigen-specific IgG response, while intramuscularly vaccinated hamsters had an early CD4+ T cell and NK cell response. Intranasal vaccination resulted in protection within 10 days with hamsters not showing clinical signs of pneumonia when challenged with three different SARS-CoV-2 variants. This data demonstrates that VSV-based vaccines are viable single-dose, fast-acting vaccine candidates that are protective from COVID-19., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 O’Donnell, Clancy, Griffin, Shifflett, Gourdine, Thomas, Long, Furuyama and Marzi.)- Published
- 2022
- Full Text
- View/download PDF
18. [Introduction of high containment laboratories in abroad].
- Author
-
Furuyama W and Nanbo A
- Abstract
Recently, outbreaks of highly pathogenic viruses, such as those of Ebola and Lassa viruses, have become a global public health issue. Such viruses must be handled in biosafety level 4 (BSL-4) laboratories. Currently, 62 BSL-4 laboratories are in operation, under construction, or planned in 24 counties. In this review, I provide an overview of the current status and characteristics of BSL-4 facilities in abroad and introduce my research on the wild-type Ebola virus at the BSL-4 facility in the USA.
- Published
- 2022
- Full Text
- View/download PDF
19. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.
- Author
-
Lai CY, To A, Ann S Wong T, Lieberman MM, Clements DE, Senda JT, Ball AH, Pessaint L, Andersen H, Furuyama W, Marzi A, Donini O, and Lehrer AT
- Abstract
The speed at which several COVID-19 vaccines went from conception to receiving FDA and EMA approval for emergency use is an achievement unrivaled in the history of vaccine development. Mass vaccination efforts using the highly effective vaccines are currently underway to generate sufficient herd immunity and reduce transmission of the SARS-CoV-2 virus. Despite the most advanced vaccine technology, global recipient coverage, especially in resource-poor areas remains a challenge as genetic drift in naïve population pockets threatens overall vaccine efficacy. In this study, we described the production of insect-cell expressed SARS-CoV-2 spike protein ectodomain constructs and examined their immunogenicity in mice. We demonstrated that, when formulated with CoVaccine HT
TM adjuvant, an oil-in-water nanoemulsion compatible with lyophilization, our vaccine candidates elicit a broad-spectrum IgG response, high neutralizing antibody (NtAb) titers against SARS-CoV-2 prototype and variants of concern, specifically B.1.351 (Beta) and P.1. (Gamma), and an antigen-specific IFN-γ secreting response in outbred mice. Of note, different ectodomain constructs yielded variations in NtAb titers against the prototype strain and some VOC. Dose response experiments indicated that NtAb titers increased with antigen dose, but not adjuvant dose, and may be higher with a lower adjuvant dose. Our findings lay the immunological foundation for the development of a dry-thermostabilized vaccine that is deployable without refrigeration., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 Published by Elsevier Ltd.)- Published
- 2021
- Full Text
- View/download PDF
20. The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway.
- Author
-
Furuyama W, Shifflett K, Feldmann H, and Marzi A
- Subjects
- Animals, Ebolavirus metabolism, HEK293 Cells, Humans, Mice, Virulence Factors metabolism, Ebolavirus pathogenicity, Hemorrhagic Fever, Ebola metabolism, MAP Kinase Signaling System physiology, Viral Proteins metabolism, Virus Replication physiology
- Abstract
Ebola virus (EBOV) expresses three different glycoproteins (GPs) from its GP gene. The primary product, soluble GP (sGP), is secreted in abundance during infection. EBOV sGP has been discussed as a potential pathogenicity factor, however, little is known regarding its functional role. Here, we analyzed the role of sGP in vitro and in vivo. We show that EBOV sGP has two different functions that contribute to infectivity in tissue culture. EBOV sGP increases the uptake of virus particles into late endosomes in HEK293 cells, and it activates the mitogen-activated protein kinase (MAPK) signaling pathway leading to increased viral replication in Huh7 cells. Furthermore, we analyzed the role of EBOV sGP on pathogenicity using a well-established mouse model. We found an sGP-dependent significant titer increase of EBOV in the liver of infected animals. These results provide new mechanistic insights into EBOV pathogenicity and highlight EBOV sGP as a possible therapeutic target., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
21. Optimization of single dose VSV-based COVID-19 vaccination in hamsters.
- Author
-
O'Donnell KL, Clancy CS, Griffin AJ, Shifflett K, Gourdine T, Thomas T, Long CM, Furuyama W, and Marzi A
- Abstract
The ongoing COVID-19 pandemic has resulted in global effects on human health, economic stability, and social norms. The emergence of viral variants raises concerns about the efficacy of existing vaccines and highlights the continued need the for the development of efficient, fast-acting, and cost-effective vaccines. Here, we demonstrate the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based vaccines encoding the SARS-CoV-2 spike protein either alone (VSV-SARS2) or in combination with the Ebola virus glycoprotein (VSV-SARS2-EBOV). Intranasally vaccinated hamsters showed an early CD8
+ T cell response in the lungs and a greater antigen-specific IgG response, while intramuscularly vaccinated hamsters had an early CD4+ T cell and NK cell response. Intranasal vaccination resulted in protection within 10 days with hamsters not showing clinical signs of pneumonia when challenged with three different SARS-CoV-2 variants. This data demonstrates that VSV-based vaccines are viable single-dose, fast-acting vaccine candidates that are protective from COVID-19.- Published
- 2021
- Full Text
- View/download PDF
22. RNA Virus-Encoded miRNAs: Current Insights and Future Challenges.
- Author
-
Nanbo A, Furuyama W, and Lin Z
- Abstract
MicroRNAs are small non-coding RNAs that regulate eukaryotic gene expression at the post-transcriptional level and affect a wide range of biological processes. Over the past two decades, numerous virus-encoded miRNAs have been identified. Some of them are crucial for viral replication, whereas others can help immune evasion. Recent sequencing-based bioinformatics methods have helped identify many novel miRNAs, which are encoded by RNA viruses. Unlike the well-characterized DNA virus-encoded miRNAs, the role of RNA virus-encoded miRNAs remains controversial. In this review, we first describe the current knowledge of miRNAs encoded by various RNA viruses, including newly emerging viruses. Next, we discuss how RNA virus-encoded miRNAs might facilitate viral replication, immunoevasion, and persistence in their hosts. Last, we briefly discuss the challenges in the experimental methodologies and potential applications of miRNAs for diagnosis and therapeutics., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Nanbo, Furuyama and Lin.)
- Published
- 2021
- Full Text
- View/download PDF
23. Ebola Virus Glycoprotein Domains Associated with Protective Efficacy.
- Author
-
Bhatia B, Furuyama W, Hoenen T, Feldmann H, and Marzi A
- Abstract
Ebola virus (EBOV) is the cause of sporadic outbreaks of human hemorrhagic disease in Africa, and the best-characterized virus in the filovirus family. The West African epidemic accelerated the clinical development of vaccines and therapeutics, leading to licensure of vaccines and antibody-based therapeutics for human use in recent years. The most widely used vaccine is based on vesicular stomatitis virus (VSV) expressing the EBOV glycoprotein (GP) (VSV-EBOV). Due to its favorable immune cell targeting, this vaccine has also been used as a base vector for the development of second generation VSV-based vaccines against Influenza, Nipah, and Zika viruses. However, in these situations, it may be beneficial if the immunogenicity against EBOV GP is minimized to induce a better protective immune response against the other foreign immunogen. Here, we analyzed if EBOV GP can be truncated to be less immunogenic, yet still able to drive replication of the vaccine vector. We found that the EBOV GP glycan cap and the mucin-like domain are both dispensable for VSV-EBOV replication. The glycan cap, however, appears critical for mediating a protective immune response against lethal EBOV challenge in mice.
- Published
- 2021
- Full Text
- View/download PDF
24. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine.
- Author
-
Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, and Marzi A
- Abstract
The ongoing pandemic of Coronavirus disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single dose, fast-acting vesicular stomatitis virus-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (IM) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (IN) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to control animals. While IM and IN vaccination both induced neutralizing antibody titers, only IM vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of IM-vaccinated animals only. Overall, the data demonstrates that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study., One Sentence Summary: VSV vaccine protects NHPs from COVID-19 in 10 days.
- Published
- 2021
- Full Text
- View/download PDF
25. A biaryl sulfonamide derivative as a novel inhibitor of filovirus infection.
- Author
-
Isono M, Furuyama W, Kuroda M, Kondoh T, Igarashi M, Kajihara M, Yoshida R, Manzoor R, Okuya K, Miyamoto H, Feldmann H, Marzi A, Sakaitani M, Nanbo A, and Takada A
- Subjects
- Animals, Chlorocebus aethiops, Drug Discovery, Ebolavirus drug effects, Filoviridae classification, Filoviridae Infections drug therapy, Filoviridae Infections virology, HEK293 Cells, Hemorrhagic Fever, Ebola drug therapy, Humans, Marburg Virus Disease drug therapy, Marburgvirus drug effects, Receptors, Virus metabolism, Vero Cells, Filoviridae drug effects, Sulfonamides chemistry, Sulfonamides pharmacology, Virus Internalization drug effects
- Abstract
Ebolaviruses and marburgviruses, members of the family Filoviridae, are known to cause fatal diseases often associated with hemorrhagic fever. Recent outbreaks of Ebola virus disease in West African countries and the Democratic Republic of the Congo have made clear the urgent need for the development of therapeutics and vaccines against filoviruses. Using replication-incompetent vesicular stomatitis virus (VSV) pseudotyped with the Ebola virus (EBOV) envelope glycoprotein (GP), we screened a chemical compound library to obtain new drug candidates that inhibit filoviral entry into target cells. We discovered a biaryl sulfonamide derivative that suppressed in vitro infection mediated by GPs derived from all known human-pathogenic filoviruses. To determine the inhibitory mechanism of the compound, we monitored each entry step (attachment, internalization, and membrane fusion) using lipophilic tracer-labeled ebolavirus-like particles and found that the compound efficiently blocked fusion between the viral envelope and the endosomal membrane during cellular entry. However, the compound did not block the interaction of GP with the Niemann-Pick C1 protein, which is believed to be the receptor of filoviruses. Using replication-competent VSVs pseudotyped with EBOV GP, we selected escape mutants and identified two EBOV GP amino acid residues (positions 47 and 66) important for the interaction with this compound. Interestingly, these amino acid residues were located at the base region of the GP trimer, suggesting that the compound might interfere with the GP conformational change required for membrane fusion. These results suggest that this biaryl sulfonamide derivative is a novel fusion inhibitor and a possible drug candidate for the development of a pan-filovirus therapeutic., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
26. Development of an Enzyme-Linked Immunosorbent Assay to Determine the Expression Dynamics of Ebola Virus Soluble Glycoprotein during Infection.
- Author
-
Furuyama W and Marzi A
- Abstract
Ebola virus (EBOV) is a highly pathogenic virus with human case fatality rates of up to 90%. EBOV uses transcriptional editing to express three different glycoproteins (GPs) from its GP gene: soluble GP (sGP), GP, and small sGP (ssGP). The molecular ratio of unedited to edited mRNA is about 70% (sGP): 25% (GP): 5% (ssGP), indicating that sGP is produced more abundantly than GP. While the presence of sGP has been confirmed in the blood during human EBOV infection, there is no report about its expression dynamics. In this study, we developed an EBOV-sGP-specific sandwich enzyme-linked immunosorbent assay (ELISA) using two different available antibodies and tested several animal serum samples to determine the concentration of sGP. EBOV-sGP was detected in nonhuman primate serum samples as early as 4 days after EBOV infection, correlating with RT-qPCR positivity. This ELISA might be further developed into a diagnostic tool for detection of EBOV in patients. Furthermore, this study provides insights into the expression dynamics of sGP during infection, which are important to decipher the function that sGP plays during infection.
- Published
- 2020
- Full Text
- View/download PDF
27. A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection.
- Author
-
Furuyama W, Nanbo A, Maruyama J, Marzi A, and Takada A
- Subjects
- Animals, Antibodies, Monoclonal immunology, Antibodies, Viral immunology, Cell Line, Chlorocebus aethiops, Ebolavirus pathogenicity, Endocytosis immunology, HEK293 Cells, Hemorrhagic Fever, Ebola pathology, Humans, Vero Cells, Viral Proteins immunology, Viral Proteins metabolism, Virus Attachment, Antibody-Dependent Enhancement immunology, Complement C1q metabolism, Ebolavirus immunology, Hemorrhagic Fever, Ebola immunology, Membrane Glycoproteins metabolism, Receptors, Complement metabolism
- Abstract
Besides the common Fc receptor (FcR)-mediated mechanism of antibody-dependent enhancement (ADE), Ebola virus (EBOV) is known to utilize the complement component C1q for ADE of infection. This mechanism is FcR-independent and mediated by cross-linking of virus-antibody-C1q complexes to cell surface C1q receptors, leading to enhanced viral entry into cells. Using confocal microscopy, we found that virus-like particles (VLPs) consisting of EBOV glycoprotein, nucleoprotein, and matrix protein attached to the surface of human kidney 293 cells more efficiently in the presence of an ADE monoclonal antibody and C1q than with the antibody or C1q alone, and that there was no significant difference in the efficiency of VLP uptake into endosomes between the C1q-mediated ADE and non-ADE entry. Accordingly, both ADE and non-ADE infection were similarly decreased by inhibitors of the signaling pathways known to be required for endocytosis. These results suggest that C1q-mediated ADE of EBOV infection is simply caused by increased attachment of virus particles to the cell surface, which is distinct from the mechanism of FcR-mediated ADE requiring intracellular signaling to promote phagocytosis/macropinocytosis., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
28. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses.
- Author
-
Saito T, Maruyama J, Nagata N, Isono M, Okuya K, Takadate Y, Kida Y, Miyamoto H, Mori-Kajihara A, Hattori T, Furuyama W, Ogawa S, Iida S, and Takada A
- Subjects
- Animals, Antibodies, Viral administration & dosage, Cricetinae, Disease Susceptibility, Drug Evaluation, Preclinical, Ebolavirus immunology, Mesocricetus, Mice, Rats, Vaccines, Synthetic, Vesicular Stomatitis pathology, Vesicular Stomatitis prevention & control, Vesicular Stomatitis therapy, Vesiculovirus pathogenicity, Viral Envelope Proteins immunology, Viral Load, Disease Models, Animal, Ebolavirus genetics, Marburgvirus genetics, Vesicular Stomatitis virology, Vesiculovirus genetics, Viral Envelope Proteins genetics
- Abstract
Filoviruses, including Ebola virus (EBOV) and Marburg virus (MARV), cause severe hemorrhagic fever in humans and nonhuman primates with high mortality rates. There is no approved therapy against these deadly viruses. Antiviral drug development has been hampered by the requirement of a biosafety level (BSL)-4 facility to handle infectious EBOV and MARV because of their high pathogenicity to humans. In this study, we aimed to establish a surrogate animal model that can be used for anti-EBOV and -MARV drug screening under BSL-2 conditions by focusing on the replication-competent recombinant vesicular stomatitis virus (rVSV) pseudotyped with the envelope glycoprotein (GP) of EBOV (rVSV/EBOV) and MARV (rVSV/MARV), which has been investigated as vaccine candidates and thus widely used in BSL-2 laboratories. We first inoculated mice, rats, and hamsters intraperitoneally with rVSV/EBOV and found that only hamsters showed disease signs and succumbed within 4 days post-infection. Infection with rVSV/MARV also caused lethal infection in hamsters. Both rVSV/EBOV and rVSV/MARV were detected at high titers in multiple organs including the liver, spleen, kidney, and lungs of infected hamsters, indicating acute and systemic infection resulting in fatal outcomes. Therapeutic effects of passive immunization with an anti-EBOV neutralizing antibody were specifically observed in rVSV/EBOV-infected hamsters. Thus, this animal model is expected to be a useful tool to facilitate in vivo screening of anti-filovirus drugs targeting the GP molecule.
- Published
- 2020
- Full Text
- View/download PDF
29. Niemann-Pick C1 Heterogeneity of Bat Cells Controls Filovirus Tropism.
- Author
-
Takadate Y, Kondoh T, Igarashi M, Maruyama J, Manzoor R, Ogawa H, Kajihara M, Furuyama W, Sato M, Miyamoto H, Yoshida R, Hill TE, Freiberg AN, Feldmann H, Marzi A, and Takada A
- Subjects
- Amino Acid Sequence, Animals, Chiroptera, Humans, Models, Molecular, Filoviridae genetics, Niemann-Pick C1 Protein metabolism, Tropism genetics
- Abstract
Fruit bats are suspected to be natural hosts of filoviruses, including Ebola virus (EBOV) and Marburg virus (MARV). Interestingly, however, previous studies suggest that these viruses have different tropisms depending on the bat species. Here, we show a molecular basis underlying the host-range restriction of filoviruses. We find that bat-derived cell lines FBKT1 and ZFBK13-76E show preferential susceptibility to EBOV and MARV, respectively, whereas the other bat cell lines tested are similarly infected with both viruses. In FBKT1 and ZFBK13-76E, unique amino acid (aa) sequences are found in the Niemann-Pick C1 (NPC1) protein, one of the cellular receptors interacting with the filovirus glycoprotein (GP). These aa residues, as well as a few aa differences between EBOV and MARV GPs, are crucial for the differential susceptibility to filoviruses. Taken together, our findings indicate that the heterogeneity of bat NPC1 orthologs is an important factor controlling filovirus species-specific host tropism., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
30. A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades.
- Author
-
Furuyama W, Reynolds P, Haddock E, Meade-White K, Quynh Le M, Kawaoka Y, Feldmann H, and Marzi A
- Abstract
The avian influenza virus outbreak in 1997 highlighted the potential of the highly pathogenic H5N1 virus to cause severe disease in humans. Therefore, effective vaccines against H5N1 viruses are needed to counter the potential threat of a global pandemic. We have previously developed a fast-acting and efficacious vaccine against Ebola virus (EBOV) using the vesicular stomatitis virus (VSV) platform. In this study, we generated recombinant VSV-based H5N1 influenza virus vectors to demonstrate the feasibility of this platform for a fast-acting pan-H5 influenza virus vaccine. We chose multiple approaches regarding antigen design and genome location to define a more optimized vaccine approach. After the VSV-based H5N1 influenza virus constructs were recovered and characterized in vitro, mice were vaccinated by a single dose or prime/boost regimen followed by challenge with a lethal dose of the homologous H5 clade 1 virus. We found that a single dose of VSV vectors expressing full-length hemagglutinin (HAfl) were sufficient to provide 100% protection. The vaccine vectors were fast-acting as demonstrated by uniform protection when administered 3 days prior to lethal challenge. Moreover, single vaccination induced cross-protective H5-specific antibodies and protected mice against lethal challenge with various H5 clade 2 viruses, highlighting the potential of the VSV-based HAfl as a pan-H5 influenza virus emergency vaccine., Competing Interests: Competing interestsH.F. claims intellectual property regarding the vesicular stomatitis virus-based vaccines for viral hemorrhagic fevers. No other competing interests are to be disclosed., (© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020.)
- Published
- 2020
- Full Text
- View/download PDF
31. Ebola Virus: Pathogenesis and Countermeasure Development.
- Author
-
Furuyama W and Marzi A
- Subjects
- Africa epidemiology, Animals, Disease Outbreaks, Drug Development, Ebola Vaccines administration & dosage, Ebola Vaccines genetics, Ebola Vaccines immunology, Ebolavirus genetics, Ebolavirus immunology, Ebolavirus pathogenicity, Hemorrhagic Fever, Ebola epidemiology, Hemorrhagic Fever, Ebola pathology, Hemorrhagic Fever, Ebola prevention & control, Humans, Ebolavirus physiology, Hemorrhagic Fever, Ebola virology
- Abstract
Since its discovery in 1976, Ebola virus (EBOV) has caused numerous outbreaks of fatal hemorrhagic disease in Africa. The biggest outbreak on record is the 2013-2016 epidemic in west Africa with almost 30,000 cases and over 11,000 fatalities, devastatingly affecting Guinea, Liberia, and Sierra Leone. The epidemic highlighted the need for licensed drugs or vaccines to quickly combat the disease. While at the beginning of the epidemic no licensed countermeasures were available, several experimental drugs with preclinical efficacy were accelerated into human clinical trials and used to treat patients with Ebola virus disease (EVD) toward the end of the epidemic. In the same manner, vaccines with preclinical efficacy were administered primarily to known contacts of EVD patients on clinical trial protocols using a ring-vaccination strategy. In this review, we describe the pathogenesis of EBOV and summarize the current status of EBOV vaccine development and treatment of EVD.
- Published
- 2019
- Full Text
- View/download PDF
32. A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector.
- Author
-
Ohtsuka J, Fukumura M, Furuyama W, Wang S, Hara K, Maeda M, Tsurudome M, Miyamoto H, Kaito A, Tsuda N, Kataoka Y, Mizoguchi A, Takada A, and Nosaka T
- Subjects
- Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Chlorocebus aethiops, Epitopes genetics, Epitopes immunology, Gene Order, Genetic Engineering, Humans, Mice, Neutralization Tests, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, Vero Cells, Genetic Vectors genetics, Parainfluenza Virus 2, Human genetics, Vaccines, Synthetic genetics, Vaccinology methods
- Abstract
Ectopic protein with proper steric structure was efficiently loaded onto the envelope of the F gene-defective BC-PIV vector derived from human parainfluenza virus type 2 (hPIV2) by a reverse genetics method of recombinant virus production. Further, ectopic antigenic peptide was successfully loaded either outside, inside, or at both sides of the envelope of the vector. The BC-PIV vector harboring the Ebola virus GP gene was able to elicit neutralizing antibodies in mice. In addition, BC-PIV with antigenic epitopes of both melanoma gp100 and WT1 tumor antigen induced a CD8+ T-cell-mediated response in tumor-transplanted syngeneic mice. Considering the low pathogenicity and recurrent infections of parental hPIV2, BC-PIV can be used as a versatile vector with high safety for recombinant vaccine development, addressing unmet medical needs.
- Published
- 2019
- Full Text
- View/download PDF
33. Generation of bat-derived influenza viruses and their reassortants.
- Author
-
Sato M, Maruyama J, Kondoh T, Nao N, Miyamoto H, Takadate Y, Furuyama W, Kajihara M, Ogawa H, Manzoor R, Yoshida R, Igarashi M, and Takada A
- Subjects
- Animals, Cell Line, Chlorocebus aethiops, Dogs, Host Specificity, Humans, Quail, South America, Virus Replication, Chiroptera virology, Influenza A virus isolation & purification, Influenza A virus pathogenicity, Influenza A virus physiology, Orthomyxoviridae Infections virology, Reassortant Viruses isolation & purification, Reassortant Viruses pathogenicity, Reassortant Viruses physiology
- Abstract
Two novel influenza A virus-like genomes were detected in fruit bats in Central and South America. However, the biological properties of these bat-derived influenza viruses (BatIVs) are still largely unknown since infectious viral particles have never been isolated from the infected host species. In this study, a reverse genetics approach was used to generate infectious BatIV particles entirely from plasmids encoding full-length sequences in eight gene segments. We inoculated BatIV particles into various cell cultures including bat-derived cell lines and found that BatIVs infected particular bat-derived cells efficiently but not the other cell lines tested. Reassortant viruses between the two BatIVs were also successfully generated and their replication in the susceptible bat cell lines was confirmed. These findings suggest a limited host range and reassortment potential of BatIVs in nature, providing fundamental information for understanding of the ecology of BatIVs.
- Published
- 2019
- Full Text
- View/download PDF
34. Seroprevalence of Filovirus Infection of Rousettus aegyptiacus Bats in Zambia.
- Author
-
Changula K, Kajihara M, Mori-Kajihara A, Eto Y, Miyamoto H, Yoshida R, Shigeno A, Hang'ombe B, Qiu Y, Mwizabi D, Squarre D, Ndebe J, Ogawa H, Harima H, Simulundu E, Moonga L, Kapila P, Furuyama W, Kondoh T, Sato M, Takadate Y, Kaneko C, Nakao R, Mukonka V, Mweene A, and Takada A
- Subjects
- Animals, Antibodies, Viral blood, Antibodies, Viral immunology, Chiroptera virology, Disease Reservoirs virology, Female, Filoviridae Infections virology, Glycoproteins blood, Glycoproteins immunology, Immunoglobulin G blood, Immunoglobulin G immunology, Male, Seroepidemiologic Studies, Zambia, Chiroptera blood, Chiroptera immunology, Filoviridae immunology, Filoviridae Infections blood, Filoviridae Infections immunology
- Abstract
Bats are suspected to play important roles in the ecology of filoviruses, including ebolaviruses and marburgviruses. A cave-dwelling fruit bat, Rousettus aegyptiacus, has been shown to be a reservoir of marburgviruses. Using an enzyme-linked immunosorbent assay with the viral glycoprotein antigen, we detected immunoglobulin G antibodies specific to multiple filoviruses in 158 of 290 serum samples of R aegyptiacus bats captured in Zambia during the years 2014-2017. In particular, 43.8% of the bats were seropositive to marburgvirus, supporting the notion that this bat species continuously maintains marburgviruses as a reservoir. Of note, distinct peaks of seropositive rates were repeatedly observed at the beginning of rainy seasons, suggesting seasonality of the presence of newly infected individuals in this bat population. These data highlight the need for continued monitoring of filovirus infection in this bat species even in countries where filovirus diseases have not been reported.
- Published
- 2018
- Full Text
- View/download PDF
35. Single-Nucleotide Polymorphisms in Human NPC1 Influence Filovirus Entry Into Cells.
- Author
-
Kondoh T, Letko M, Munster VJ, Manzoor R, Maruyama J, Furuyama W, Miyamoto H, Shigeno A, Fujikura D, Takadate Y, Yoshida R, Igarashi M, Feldmann H, Marzi A, and Takada A
- Subjects
- Animals, Cell Line, Chlorocebus aethiops, HEK293 Cells, Humans, Intracellular Signaling Peptides and Proteins, Niemann-Pick C1 Protein, Receptors, Virus metabolism, Vero Cells, Viral Envelope Proteins metabolism, Virus Internalization, Carrier Proteins genetics, Ebolavirus pathogenicity, Hemorrhagic Fever, Ebola genetics, Hemorrhagic Fever, Ebola virology, Membrane Glycoproteins genetics, Polymorphism, Single Nucleotide genetics
- Abstract
Niemann-Pick C1 (NPC1), a host receptor involved in the envelope glycoprotein (GP)-mediated entry of filoviruses into cells, is believed to be a major determinant of cell susceptibility to filovirus infection. It is known that proteolytically digested Ebola virus (EBOV) GP interacts with 2 protruding loops in domain C of NPC1. Using previously published structural data and the National Center for Biotechnology Information Single-Nucleotide Polymorphism (SNP) database, we identified 10 naturally occurring missense SNPs in human NPC1. To investigate whether these SNPs affect cell susceptibility to filovirus infection, we generated Vero E6 cell lines stably expressing NPC1 with SNP substitutions and compared their susceptibility to vesicular stomatitis virus pseudotyped with filovirus GPs and infectious EBOV. We found that some of the substitutions resulted in reduced susceptibility to filoviruses, as indicated by the lower titers and smaller plaque/focus sizes of the viruses. Our data suggest that human NPC1 SNPs may likely affect host susceptibility to filoviruses.
- Published
- 2018
- Full Text
- View/download PDF
36. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.
- Author
-
Suder E, Furuyama W, Feldmann H, Marzi A, and de Wit E
- Subjects
- Animals, Clinical Trials as Topic, Drug Evaluation, Preclinical, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Ebola Vaccines administration & dosage, Ebola Vaccines genetics, Humans, Vaccines, Attenuated administration & dosage, Vaccines, Attenuated genetics, Vaccines, Attenuated immunology, Vaccines, Attenuated isolation & purification, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Vaccines, Synthetic isolation & purification, Drug Carriers, Ebola Vaccines immunology, Ebola Vaccines isolation & purification, Hemorrhagic Fever, Ebola prevention & control, Vesiculovirus genetics
- Abstract
The devastating Ebola virus (EBOV) epidemic in West Africa in 2013-2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the EBOV glycoprotein (VSV-EBOV). Extensive preclinical testing in animal models demonstrated the prophylactic and post-exposure efficacy of this vaccine, identified the mechanism of protection, and suggested it was safe for human use. Based on these data, VSV-EBOV was extensively tested in phase 1-3 clinical trials in North America, Europe and Africa. Although some side effects of vaccination were observed, these clinical trials showed that the VSV-EBOV was safe and immunogenic in humans. Moreover, the data supported the use of VSV-EBOV as an emergency vaccine in individuals at risk for Ebola virus disease. In this review, we summarize the results of the extensive preclinical and clinical testing of the VSV-EBOV vaccine.
- Published
- 2018
- Full Text
- View/download PDF
37. Putative endogenous filovirus VP35-like protein potentially functions as an IFN antagonist but not a polymerase cofactor.
- Author
-
Kondoh T, Manzoor R, Nao N, Maruyama J, Furuyama W, Miyamoto H, Shigeno A, Kuroda M, Matsuno K, Fujikura D, Kajihara M, Yoshida R, Igarashi M, and Takada A
- Subjects
- Amino Acid Sequence, Animals, Chiroptera virology, Ebolavirus isolation & purification, Ebolavirus metabolism, Gene Expression, Genes, Reporter, HEK293 Cells, Humans, Interferon-beta genetics, Interferon-beta immunology, Luciferases genetics, Luciferases metabolism, Nucleocapsid Proteins, Nucleoproteins metabolism, Promoter Regions, Genetic, Protein Binding, RNA, Double-Stranded metabolism, Recombinant Proteins genetics, Recombinant Proteins metabolism, Sequence Alignment, Sequence Homology, Amino Acid, Viral Core Proteins metabolism, Virus Replication, Ebolavirus genetics, Host-Pathogen Interactions, Interferon-beta antagonists & inhibitors, Nucleoproteins genetics, RNA, Double-Stranded genetics, Viral Core Proteins genetics
- Abstract
It has been proposed that some non-retroviral RNA virus genes are integrated into vertebrate genomes. Endogenous filovirus-like elements (EFLs) have been discovered in some mammalian genomes. However, their potential roles in ebolavirus infection are unclear. A filovirus VP35-like element (mlEFL35) is found in the little brown bat (Myotis lucifugus) genome. Putative mlEFL35-derived protein (mlEFL35p) contains nearly full-length amino acid sequences corresponding to ebolavirus VP35. Ebola virus VP35 has been shown to bind double-stranded RNA, leading to inhibition of type I interferon (IFN) production, and is also known as a viral polymerase cofactor that is essential for viral RNA transcription/replication. In this study, we transiently expressed mlEFL35p in human kidney cells and investigated its biological functions. We first found that mlEFL35p was coimmunoprecipitated with itself and ebolavirus VP35s but not with the viral nucleoprotein. Then the biological functions of mlEFL35p were analyzed by comparing it to ebolavirus VP35s. We found that the expression of mlEFL35p significantly inhibited human IFN-β promoter activity as well as VP35s. By contrast, expression of mlEFL35p did not support viral RNA transcription/replication and indeed slightly decrease the reporter gene expression in a minigenome assay. These results suggest that mlEFL35p potentially acts as an IFN antagonist but not a polymerase cofactor.
- Published
- 2017
- Full Text
- View/download PDF
38. Genetic Predisposition To Acquire a Polybasic Cleavage Site for Highly Pathogenic Avian Influenza Virus Hemagglutinin.
- Author
-
Nao N, Yamagishi J, Miyamoto H, Igarashi M, Manzoor R, Ohnuma A, Tsuda Y, Furuyama W, Shigeno A, Kajihara M, Kishida N, Yoshida R, and Takada A
- Subjects
- Adenine chemistry, Animals, Chickens virology, Guanine chemistry, Hemagglutinin Glycoproteins, Influenza Virus chemistry, Hemagglutinin Glycoproteins, Influenza Virus classification, High-Throughput Nucleotide Sequencing, Influenza A Virus, H5N1 Subtype chemistry, Influenza in Birds, RNA, Viral chemistry, Virulence, Genetic Predisposition to Disease, Hemagglutinin Glycoproteins, Influenza Virus genetics, Influenza A Virus, H5N1 Subtype genetics, Influenza A Virus, H5N1 Subtype pathogenicity, RNA, Viral genetics
- Abstract
Highly pathogenic avian influenza viruses with H5 and H7 hemagglutinin (HA) subtypes evolve from low-pathogenic precursors through the acquisition of multiple basic amino acid residues at the HA cleavage site. Although this mechanism has been observed to occur naturally only in these HA subtypes, little is known about the genetic basis for the acquisition of the polybasic HA cleavage site. Here we show that consecutive adenine residues and a stem-loop structure, which are frequently found in the viral RNA region encoding amino acids around the cleavage site of low-pathogenic H5 and H7 viruses isolated from waterfowl reservoirs, are important for nucleotide insertions into this RNA region. A reporter assay to detect nontemplated nucleotide insertions and deep-sequencing analysis of viral RNAs revealed that an increased number of adenine residues and enlarged stem-loop structure in the RNA region accelerated the multiple adenine and/or guanine insertions required to create codons for basic amino acids. Interestingly, nucleotide insertions associated with the HA cleavage site motif were not observed principally in the viral RNA of other subtypes tested (H1, H2, H3, and H4). Our findings suggest that the RNA editing-like activity is the key mechanism for nucleotide insertions, providing a clue as to why the acquisition of the polybasic HA cleavage site is restricted to the particular HA subtypes. IMPORTANCE Influenza A viruses are divided into subtypes based on the antigenicity of the viral surface glycoproteins hemagglutinin (HA) and neuraminidase. Of the 16 HA subtypes (H1 to -16) maintained in waterfowl reservoirs of influenza A viruses, H5 and H7 viruses often become highly pathogenic through the acquisition of multiple basic amino acid residues at the HA cleavage site. Although this mechanism has been known since the 1980s, the genetic basis for nucleotide insertions has remained unclear. This study shows the potential role of the viral RNA secondary structure for nucleotide insertions and demonstrates a key mechanism explaining why the acquisition of the polybasic HA cleavage site is restricted to particular HA subtypes in nature. Our findings will contribute to better understanding of the ecology of influenza A viruses and will also be useful for the development of genetically modified vaccines against H5 and H7 influenza A viruses with increased stability., (Copyright © 2017 Nao et al.)
- Published
- 2017
- Full Text
- View/download PDF
39. Quantification of Filovirus Glycoprotein-Specific Antibodies.
- Author
-
Furuyama W, Miyamoto H, Yoshida R, and Takada A
- Subjects
- Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Antibodies, Viral isolation & purification, Ebolavirus immunology, Ebolavirus pathogenicity, Glycoproteins immunology, Glycoproteins isolation & purification, Hemorrhagic Fever, Ebola prevention & control, Hemorrhagic Fever, Ebola virology, Humans, Viral Vaccines pharmacology, Antibodies, Neutralizing isolation & purification, Enzyme-Linked Immunosorbent Assay methods, Hemorrhagic Fever, Ebola immunology, Viral Vaccines immunology
- Abstract
Serological methods such as the enzyme-linked immunosorbent assay (ELISA) and virus neutralization test are fundamental tools used in diagnosis, seroepidemiological studies of filovirus transmission/prevalence, and the evaluation of vaccine immunogenicity and potential therapeutic antibodies. Filoviruses have a single transmembrane glycoprotein (GP), which is the only known target of neutralizing antibodies. Here we describe serological methods to quantify filovirus GP-specific antibodies.
- Published
- 2017
- Full Text
- View/download PDF
40. Fcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection.
- Author
-
Furuyama W, Marzi A, Carmody AB, Maruyama J, Kuroda M, Miyamoto H, Nanbo A, Manzoor R, Yoshida R, Igarashi M, Feldmann H, and Takada A
- Subjects
- Animals, Antibodies, Viral immunology, Chlorocebus aethiops, Gene Knockdown Techniques, HEK293 Cells, Hemorrhagic Fever, Ebola metabolism, Humans, Jurkat Cells, K562 Cells, Vero Cells, Virus Internalization, Antibody-Dependent Enhancement immunology, Hemorrhagic Fever, Ebola immunology, Receptors, IgG immunology, Signal Transduction immunology, src-Family Kinases immunology
- Abstract
Antibody-dependent enhancement (ADE) of Ebola virus (EBOV) infection has been demonstrated in vitro, raising concerns about the detrimental potential of some anti-EBOV antibodies. ADE has been described for many viruses and mostly depends on the cross-linking of virus-antibody complexes to cell surface Fc receptors, leading to enhanced infection. However, little is known about the molecular mechanisms underlying this phenomenon. Here we show that Fcγ-receptor IIa (FcγRIIa)-mediated intracellular signaling through Src family protein tyrosine kinases (PTKs) is required for ADE of EBOV infection. We found that deletion of the FcγRIIa cytoplasmic tail abolished EBOV ADE due to decreased virus uptake into cellular endosomes. Furthermore, EBOV ADE, but not non-ADE infection, was significantly reduced by inhibition of the Src family protein PTK pathway, which was also found to be important to promote phagocytosis/macropinocytosis for viral uptake into endosomes. We further confirmed a significant increase of the Src phosphorylation mediated by ADE. These data suggest that antibody-EBOV complexes bound to the cell surface FcγRIIa activate the Src signaling pathway that leads to enhanced viral entry into cells, providing a novel perspective for the general understanding of ADE of virus infection., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF
41. Development of an Immunochromatography Assay (QuickNavi-Ebola) to Detect Multiple Species of Ebolaviruses.
- Author
-
Yoshida R, Muramatsu S, Akita H, Saito Y, Kuwahara M, Kato D, Changula K, Miyamoto H, Kajihara M, Manzoor R, Furuyama W, Marzi A, Feldmann H, Mweene A, Masumu J, Kapeteshi J, Muyembe-Tamfum JJ, and Takada A
- Subjects
- Africa, Western epidemiology, Animals, Antibodies, Viral blood, Ebolavirus isolation & purification, Enzyme-Linked Immunosorbent Assay, Hemorrhagic Fever, Ebola epidemiology, Hemorrhagic Fever, Ebola virology, Humans, Nucleoproteins immunology, Antibodies, Monoclonal immunology, Antigens, Viral immunology, Chromatography, Affinity methods, Disease Outbreaks, Ebolavirus immunology, Hemorrhagic Fever, Ebola diagnosis
- Abstract
The latest outbreak of Ebola virus disease (EVD) in West Africa has highlighted the urgent need for the development of rapid and reliable diagnostic assays. We used monoclonal antibodies specific to the ebolavirus nucleoprotein to develop an immunochromatography (IC) assay (QuickNavi-Ebola) for rapid diagnosis of EVD. The IC assay was first evaluated with tissue culture supernatants of infected Vero E6 cells and found to be capable of detecting 10
3 -104 focus-forming units/mL of ebolaviruses. Using serum samples from experimentally infected nonhuman primates, we confirmed that the assay could detect the viral antigen shortly after disease onset. It was also noted that multiple species of ebolaviruses could be detected by the IC assay. Owing to the simplicity of the assay procedure and absence of requirements for special equipment and training, QuickNavi-Ebola is expected to be a useful tool for rapid diagnosis of EVD., (© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.)- Published
- 2016
- Full Text
- View/download PDF
42. Discovery of an antibody for pan-ebolavirus therapy.
- Author
-
Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, Miyamoto H, Igarashi M, Yoshida R, Noyori O, Feldmann H, and Takada A
- Subjects
- Amino Acid Sequence, Animals, Antibodies, Monoclonal immunology, Antibodies, Monoclonal pharmacology, Antibodies, Neutralizing immunology, Antibodies, Neutralizing pharmacology, Chlorocebus aethiops, Disease Models, Animal, Ebolavirus metabolism, Epitopes chemistry, Epitopes immunology, Female, Hemorrhagic Fever, Ebola mortality, Hemorrhagic Fever, Ebola veterinary, Humans, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Molecular Sequence Data, Protein Structure, Tertiary, Receptor, Interferon alpha-beta deficiency, Receptor, Interferon alpha-beta genetics, Sequence Alignment, Survival Rate, Vero Cells, Virus Internalization drug effects, Antibodies, Monoclonal therapeutic use, Antibodies, Neutralizing therapeutic use, Hemorrhagic Fever, Ebola drug therapy
- Abstract
During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. However, due to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal antibodies are only effective against viruses of the species Zaire ebolavirus. Although this particular species has indeed caused the majority of human infections in Central and, recently, West Africa, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeatedly caused outbreaks in Central Africa and thus should not be neglected in the development of countermeasures against ebolaviruses. Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody that effectively inhibits cellular entry of representative isolates of all known ebolavirus species in vitro and show its protective efficacy in mouse models of ebolavirus infections. This novel neutralizing monoclonal antibody targets a highly conserved internal fusion loop in the glycoprotein molecule and prevents membrane fusion of the viral envelope with cellular membranes. The discovery of this highly cross-neutralizing antibody provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of improved vaccines that can selectively elicit cross-neutralizing antibodies against multiple species of ebolaviruses.
- Published
- 2016
- Full Text
- View/download PDF
43. Ebola vaccine, therapeutics, and diagnostics.
- Author
-
Furuyama W and Takada A
- Subjects
- Africa, Western epidemiology, Animals, Clinical Trials as Topic, Disease Outbreaks prevention & control, Hemorrhagic Fever, Ebola diagnosis, Hemorrhagic Fever, Ebola epidemiology, Humans, Research, Ebola Vaccines, Hemorrhagic Fever, Ebola prevention & control, Hemorrhagic Fever, Ebola therapy
- Abstract
Ebolaviruses, members of the family Filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates, with human case fatality rates of up to 90%. No effective prophylaxis or treatment for Ebola virus disease (EVD) is yet commercially available. During the latest outbreak of EVD in West Africa, several unapproved drugs were used for the treatment of patients. This outbreak has indeed accelerated efforts to develop antiviral strategies and some of the vaccine and drug candidates have undergone clinical trials. This article reviews previous researches and recent advances on the development of vaccine, therapeutics, and diagnostics for EVD.
- Published
- 2016
- Full Text
- View/download PDF
44. Genetic and antigenic characterization of H5 and H7 influenza viruses isolated from migratory water birds in Hokkaido, Japan and Mongolia from 2010 to 2014.
- Author
-
Hiono T, Ohkawara A, Ogasawara K, Okamatsu M, Tamura T, Chu DH, Suzuki M, Kuribayashi S, Shichinohe S, Takada A, Ogawa H, Yoshida R, Miyamoto H, Nao N, Furuyama W, Maruyama J, Eguchi N, Ulziibat G, Enkhbold B, Shatar M, Jargalsaikhan T, Byambadorj S, Damdinjav B, Sakoda Y, and Kida H
- Subjects
- Animals, Birds, Cluster Analysis, Feces virology, Genetic Variation, Japan, Molecular Sequence Data, Mongolia, Phylogeny, RNA, Viral genetics, Sequence Analysis, DNA, Sequence Homology, Antigens, Viral analysis, Antigens, Viral genetics, Influenza A virus genetics, Influenza A virus isolation & purification, Influenza in Birds virology
- Abstract
Migratory water birds are the natural reservoir of influenza A viruses. H5 and H7 influenza viruses are isolated over the world and also circulate among poultry in Asia. In 2010, two H5N1 highly pathogenic avian influenza viruses (HPAIVs) were isolated from fecal samples of water birds on the flyway of migration from Siberia, Russia to the south in Hokkaido, Japan. H7N9 viruses are sporadically isolated from humans and circulate in poultry in China. To monitor whether these viruses have spread in the wild bird population, we conducted virological surveillance of avian influenza in migratory water birds in autumn from 2010 to 2014. A total of 8103 fecal samples from migratory water birds were collected in Japan and Mongolia, and 350 influenza viruses including 13 H5 and 19 H7 influenza viruses were isolated. A phylogenetic analysis revealed that all isolates are genetically closely related to viruses circulating among wild water birds. The results of the antigenic analysis indicated that the antigenicity of viruses in wild water birds is highly stable despite their nucleotide sequence diversity but is distinct from that of HPAIVs recently isolated in Asia. The present results suggest that HPAIVs and Chinese H7N9 viruses were not predominantly circulating in migratory water birds; however, continued monitoring of H5 and H7 influenza viruses both in domestic and wild birds is recommended for the control of avian influenza.
- Published
- 2015
- Full Text
- View/download PDF
45. Simultaneous administration of 2-aminoethyl diphenylborinate and chloroquine reverses chloroquine resistance in malaria parasites.
- Author
-
Mossaad E, Furuyama W, Enomoto M, Kawai S, Mikoshiba K, and Kawazu S
- Subjects
- Animals, Female, Inhibitory Concentration 50, Malaria drug therapy, Malaria parasitology, Mice, Mice, Inbred ICR, Verapamil therapeutic use, Antimalarials therapeutic use, Chloroquine therapeutic use, Plasmodium falciparum drug effects, Plasmodium falciparum pathogenicity
- Abstract
A nearly complete reversal of chloroquine (CQ) resistance in the CQ-resistant Plasmodium falciparum K-1 strain, with a significant decrease in the mean ± standard deviation (SD) 50% inhibitory concentration (IC50) from 1,050 ± 95 nM to 14 ± 2 nM, was achieved in vitro by the simultaneous administration of 2-aminoethyl diphenylborinate (2-APB). The CQ resistance-reversing activity of 2-APB, which showed the same efficacy as verapamil, was also observed in an in vivo mouse infection model with the CQ-resistant Plasmodium chabaudi AS(30CQ) strain., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
46. An interplay between 2 signaling pathways: melatonin-cAMP and IP3-Ca2+ signaling pathways control intraerythrocytic development of the malaria parasite Plasmodium falciparum.
- Author
-
Furuyama W, Enomoto M, Mossaad E, Kawai S, Mikoshiba K, and Kawazu S
- Subjects
- Animals, Humans, Imines pharmacology, Malaria, Falciparum parasitology, Models, Biological, Plasmodium falciparum drug effects, Receptors, Melatonin antagonists & inhibitors, Signal Transduction drug effects, Tryptamines pharmacology, Calcium Signaling drug effects, Cyclic AMP metabolism, Erythrocytes parasitology, Inositol 1,4,5-Trisphosphate metabolism, Melatonin metabolism, Plasmodium falciparum growth & development, Plasmodium falciparum metabolism
- Abstract
Plasmodium falciparum spends most of its asexual life cycle within human erythrocytes, where proliferation and maturation occur. Development into the mature forms of P. falciparum causes severe symptoms due to its distinctive sequestration capability. However, the physiological roles and the molecular mechanisms of signaling pathways that govern development are poorly understood. Our previous study showed that P. falciparum exhibits stage-specific spontaneous Calcium (Ca(2+)) oscillations in ring and early trophozoites, and the latter was essential for parasite development. In this study, we show that luzindole (LZ), a selective melatonin receptor antagonist, inhibits parasite growth. Analyses of development and morphology of LZ-treated P. falciparum revealed that LZ severely disrupted intraerythrocytic maturation, resulting in parasite death. When LZ was added at ring stage, the parasite could not undergo further development, whereas LZ added at the trophozoite stage inhibited development from early into late schizonts. Live-cell Ca(2+) imaging showed that LZ treatment completely abolished Ca(2+) oscillation in the ring forms while having little effect on early trophozoites. Further, the melatonin-induced cAMP increase observed at ring and late trophozoite stage was attenuated by LZ treatment. These suggest that a complex interplay between IP3-Ca(2+) and cAMP signaling pathways is involved in intraerythrocytic development of P. falciparum., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
47. Blockage of spontaneous Ca2+ oscillation causes cell death in intraerythrocitic Plasmodium falciparum.
- Author
-
Enomoto M, Kawazu S, Kawai S, Furuyama W, Ikegami T, Watanabe J, and Mikoshiba K
- Subjects
- Antimalarials pharmacology, Boron Compounds pharmacology, Cell Death, Chloroquine pharmacology, Drug Resistance, Erythrocytes metabolism, Humans, Plasmodium falciparum growth & development, Trophozoites drug effects, Calcium Signaling, Erythrocytes parasitology, Plasmodium falciparum drug effects, Plasmodium falciparum metabolism
- Abstract
Malaria remains one of the world's most important infectious diseases and is responsible for enormous mortality and morbidity. Resistance to antimalarial drugs is a challenging problem in malaria control. Clinical malaria is associated with the proliferation and development of Plasmodium parasites in human erythrocytes. Especially, the development into the mature forms (trophozoite and schizont) of Plasmodium falciparum (P. falciparum) causes severe malaria symptoms due to a distinctive property, sequestration which is not shared by any other human malaria. Ca(2+) is well known to be a highly versatile intracellular messenger that regulates many different cellular processes. Cytosolic Ca(2+) increases evoked by extracellular stimuli are often observed in the form of oscillating Ca(2+) spikes (Ca(2+) oscillation) in eukaryotic cells. However, in lower eukaryotic and plant cells the physiological roles and the molecular mechanisms of Ca(2+) oscillation are poorly understood. Here, we showed the observation of the inositol 1,4,5-trisphospate (IP(3))-dependent spontaneous Ca(2+) oscillation in P. falciparum without any exogenous extracellular stimulation by using live cell fluorescence Ca(2+) imaging. Intraerythrocytic P. falciparum exhibited stage-specific Ca(2+) oscillations in ring form and trophozoite stages which were blocked by IP(3) receptor inhibitor, 2-aminoethyl diphenylborinate (2-APB). Analyses of parasitaemia and parasite size and electron micrograph of 2-APB-treated P. falciparum revealed that 2-APB severely obstructed the intraerythrocytic maturation, resulting in cell death of the parasites. Furthermore, we confirmed the similar lethal effect of 2-APB on the chloroquine-resistant strain of P. falciparum. To our best knowledge, we for the first time showed the existence of the spontaneous Ca(2+) oscillation in Plasmodium species and clearly demonstrated that IP(3)-dependent spontaneous Ca(2+) oscillation in P. falciparum is critical for the development of the blood stage of the parasites. Our results provide a novel concept that IP(3)/Ca(2+) signaling pathway in the intraerythrocytic malaria parasites is a promising target for antimalarial drug development.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.